D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 42.33 CNY -1.17% Market Closed
Market Cap: 17.6B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Other Current Liabilities
ÂĄ57.2m
CAGR 3-Years
76%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Current Liabilities
ÂĄ1.5B
CAGR 3-Years
-7%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Other Current Liabilities
ÂĄ1.8B
CAGR 3-Years
38%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Current Liabilities
ÂĄ1.9B
CAGR 3-Years
53%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Current Liabilities
ÂĄ2.5B
CAGR 3-Years
23%
CAGR 5-Years
55%
CAGR 10-Years
58%
Imeik Technology Development Co Ltd
SZSE:300896
Other Current Liabilities
ÂĄ121.8m
CAGR 3-Years
33%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
17.3B CNY
Industry
Biotechnology

In the heart of China's vibrant pharmaceutical landscape lies Dizal Jiangsu Pharmaceutical Co Ltd, a dynamic company at the forefront of innovative drug development. Founded as a joint venture with a vision to bridge unmet medical needs, Dizal focuses primarily on oncology and immunology. This firm thrives on its strong pipeline of next-generation therapies, nurtured by a robust research and development arm. Collaborating with global biotech entities, it leverages cutting-edge technologies and deep scientific acumen to create breakthrough biologic and small molecule drugs that hold the potential to transform patient outcomes. Dizal’s research hubs are bustling with expert scientists dedicated to translating scientific discoveries into tangible therapies, positioning the company as a significant player in the biopharmaceutical sector. Dizal makes its money through a well-orchestrated stream of activities emphasizing strategic partnerships, intellectual property licensing, and product sales. By forging alliances with industry giants for co-development and commercialization, the company ensures a wider reach and impactful roll-out of its products. Additionally, the progressive monetization strategy of awarding patents and licenses in conjunction with its proprietary compounds enables a steady revenue inflow. This symbiotic model not only empowers Dizal to fund further innovative research but also reinforces its stature within the competitive arena of drug development. As healthcare demands continuously evolve, Dizal’s revenue generation strategies remain agile, marrying scientific ingenuity with strategic foresight.

Intrinsic Value
29.34 CNY
Overvaluation 31%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Current Liabilities?
Other Current Liabilities
57.2m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Other Current Liabilities amounts to 57.2m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
17%

Over the last year, the Other Current Liabilities growth was 154%. The average annual Other Current Liabilities growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 76% over the past three years , 17% over the past five years .

Back to Top